ES8501232A1 - Medicine prescription - Google Patents
Medicine prescriptionInfo
- Publication number
- ES8501232A1 ES8501232A1 ES522677A ES522677A ES8501232A1 ES 8501232 A1 ES8501232 A1 ES 8501232A1 ES 522677 A ES522677 A ES 522677A ES 522677 A ES522677 A ES 522677A ES 8501232 A1 ES8501232 A1 ES 8501232A1
- Authority
- ES
- Spain
- Prior art keywords
- pref
- peg
- formulation
- deriv
- esp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 150000002148 esters Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 abstract 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 abstract 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 abstract 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 abstract 1
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- -1 alkali metal salts Chemical class 0.000 abstract 1
- 125000005907 alkyl ester group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000000843 anti-fungal effect Effects 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 239000003429 antifungal agent Substances 0.000 abstract 1
- 229940121375 antifungal agent Drugs 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 208000032625 disorder of ear Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 1
- MINDHVHHQZYEEK-HBBNESRFSA-N mupirocin Chemical compound C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-HBBNESRFSA-N 0.000 abstract 1
- 229960003128 mupirocin Drugs 0.000 abstract 1
- 229930194369 pseudomonic acid Natural products 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
- 239000012049 topical pharmaceutical composition Substances 0.000 abstract 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Topical formulation contains pseudomonic acid (I) or its salt or ester and at least 1 wt.% of a poly (opt. substd. alkylene) glycol (II) or its deriv. Pref. salts of (I) are the alkali metal salts and pref. esters are the 1-4C alkyl esters. The formulation pref. contains 0.01-50 wt.% (I) (or salt or ester). Pref. (II) is polyethylene glycol (PEG) or its deriv. (esp. PEG 400 opt. contg. PEG 4000, glycofurol or cetomacrogol). The formulation may also contain antibacterial, antifungal, antiviral and/or antiinflammatory agents but pref. (I) is the sole therapeutic agent. Use amt. of (I) is esp. 0.5-10 (partic. 2) wt.%.S (I) is a known antibiotic (see GB1395907) useful for treating skin, ear and eye disorders by topical admin. (I) has improved stability in presence of (II).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8215684 | 1982-05-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES522677A0 ES522677A0 (en) | 1984-12-01 |
| ES8501232A1 true ES8501232A1 (en) | 1984-12-01 |
Family
ID=10530708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES522677A Expired ES8501232A1 (en) | 1982-05-28 | 1983-05-24 | Medicine prescription |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPS58219108A (en) |
| ES (1) | ES8501232A1 (en) |
| ZA (1) | ZA833692B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016006153A2 (en) * | 2013-09-20 | 2017-08-01 | Santen Pharmaceutical Co Ltd | composition containing polyethylene glycol |
-
1983
- 1983-05-23 ZA ZA833692A patent/ZA833692B/en unknown
- 1983-05-24 ES ES522677A patent/ES8501232A1/en not_active Expired
- 1983-05-24 JP JP9139083A patent/JPS58219108A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| ES522677A0 (en) | 1984-12-01 |
| JPH0348886B2 (en) | 1991-07-25 |
| ZA833692B (en) | 1985-02-27 |
| JPS58219108A (en) | 1983-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IE831205L (en) | Pharmaceutical formulations. | |
| UA41906C2 (en) | Method for treating neurological disorders due to trauma | |
| AU549481B2 (en) | Hair growing agent | |
| NL950022I2 (en) | Analogues of mevalolactone and derivatives thereof, methods of their preparation, pharmaceutical preparations containing them and their use as pharmaceuticals. | |
| EP0285008A3 (en) | The use of buspirone for preparing a pharmaceutical composition for the treatment of alcohol abuse | |
| CA2125662A1 (en) | Transdermally administered system containing acetylsalicylic acid for thrombosis therapy and cancer prophylaxis | |
| IT8323773U1 (en) | Guide means for the extraction of drawers or similar | |
| ES8801207A1 (en) | Dihydropyridine-carboxylic acid amides, process for their preparation and their use in medicaments. | |
| EP0235589A3 (en) | Use of quinolone and naphthyridine antibiotics for the manufacture of ophthalmic medicaments | |
| MY104006A (en) | 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases. | |
| FR2432520A1 (en) | NOVEL IMIDAZOQUINOXALINS AND THEIR SALTS, THEIR PREPARATION PROCESS, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| ES8501232A1 (en) | Medicine prescription | |
| LU90791I2 (en) | Potentiator of antineoplastic effects and antineoplastic agent | |
| IE56648B1 (en) | Polyether compounds | |
| EP0471388A3 (en) | Medicament for the treatment of cardiac insufficiency | |
| GB2122197B (en) | Antiviral guanine derivatives | |
| TW258733B (en) | ||
| IL57433A (en) | Pharmaceutical compositions containing cyclopentane derivatives | |
| DE3168004D1 (en) | Ophthalmic composition of 5-fluoro-2-methyl-1-(p-methylthio-benzylidene)-3-indenylacetic acid or salt thereof | |
| EP0294814A3 (en) | Treating agents for renal diseases | |
| IT7945204A0 (en) | PHARMACEUTICAL COMPOSITION FOR THE THERAPY OF MALE STERILITY | |
| MY110416A (en) | Composition for the treatment of schizophrenia. |